{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-009737","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.243788+00:00","generated_at":"2026-06-04T21:59:52.023552+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Interpace Biosciences reports record FY2023 revenue $40.2M (+26% YoY), swings to profit of $1.1M.","bullets":["Q4 revenue $10.3M (+23% YoY); Q4 income from cont. ops $0.8M vs loss of $1.4M in prior year.","FY2023 adjusted EBITDA $4.5M (net of one-time charges) vs -$1.2M in 2022, a 463% reported improvement.","Cash collections for FY2023 $40.4M (+29% YoY); cash balance at Dec 31, 2023 was $3.5M.","Dr. Nicole Massoll appointed Chief Medical Officer effective March 2024.","10-K expected week of March 19, 2024; preliminary results subject to final audit."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-009737","json":"https://secwatch.observer/filing/0001493152-24-009737.json","markdown":"https://secwatch.observer/filing/0001493152-24-009737.md","text":"https://secwatch.observer/filing/0001493152-24-009737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315224009737/0001493152-24-009737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315224009737/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T21:59:52.023552+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"068385443f0f4c8b73436b477670d1e2c73faa17","claim":"INTERPACE BIOSCIENCES, INC. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"On March 7, 2024, Interpace Biosciences, Inc. issued a press release announcing its preliminary results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315224009737/0001493152-24-009737-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}